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Abstract
We previously showed that middle-aged female rats sustain a larger infarct following experimental stroke as compared to
younger female rats, and paradoxically, estrogen treatment to the older group is neurotoxic. Plasma and brain insulin-like
growth factor-1 (IGF-1) levels decrease with age. However, IGF-1 infusion following stroke, prevents estrogen neurotoxicity
in middle-aged female rats. IGF1 is neuroprotective and well tolerated, but also has potentially undesirable side effects. We
hypothesized that microRNAs (miRNAs) that target the IGF-1 signaling family for translation repression could be
alternatively suppressed to promote IGF-1-like neuroprotection. Here, we report that two conserved IGF pathway regulatory
microRNAs, Let7f and miR1, can be inhibited to mimic and even extend the neuroprotection afforded by IGF-1. Anti-mir1
treatment, as late as 4 hours following ischemia, significantly reduced cortical infarct volume in adult female rats, while anti-
Let7 robustly reduced both cortical and striatal infarcts, and preserved sensorimotor function and interhemispheric neural
integration. No neuroprotection was observed in animals treated with a brain specific miRNA unrelated to IGF-1 (anti-
miR124). Remarkably, anti-Let7f was only effective in intact females but not males or ovariectomized females indicating that
the gonadal steroid environment critically modifies miRNA action. Let7f is preferentially expressed in microglia in the
ischemic hemisphere and confirmed in ex vivo cultures of microglia obtained from the cortex. While IGF-1 was undetectable
in microglia harvested from the non-ischemic hemisphere, IGF-1 was expressed by microglia obtained from the ischemic
cortex and was further elevated by anti-Let7f treatment. Collectively these data support a novel miRNA-based therapeutic
strategy for neuroprotection following stroke.
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Introduction
The risk of ischemic stroke increases substantially with age,
making it the third leading cause of death and the leading cause of
long-term disability. With age, women are more likely to suffer
stroke and to have more severe stroke outcomes compared to men
in the same age group [1]. However, tissue Plasminogen Activator
(t-PA), the only currently FDA-approved therapy, is prescribed at
lower rates to women than to men stroke patients [2]. Moreover,
current opinion supports the need for combining established
thrombolytic therapy with effective neuroprotective therapy.
Non-coding RNAs, such as microRNAs (miRNAs) that function
as translational repressors are an important regulatory element in
both tissue development and disease [3–5]. MiRNAs are
dysregulated in neurological disorders including stroke and
potential therapeutic applications of miRNA have been reported
in peripheral and central diseases [6,7]. Recent studies have
identified stroke-induced miRNA in brain and plasma from
experimental models and patients [8–10]. Additionally, miR120 is
positively correlated with better prognosis in stroke patients [11].
Furthermore, antagonists to miR497, infused prior to stroke,
reduce infarct volume [12]. However, to date, no neuroprotective
miRNA mimics or antagomirs have been identified that are
effective when delivered post-stroke.
To identify neuroprotective miRNAs, we used an alternate
strategy by interrogating the 39 UTR of a known neuroprotectant,
Insulin-like Growth Factor (IGF)-1, for specific miRNA target
sites, with the goal of inhibiting these miRNA to elevate local levels
of IGF-1 post-stroke. Insulin-like growth factor (IGF)-1 is a critical
endogenous neuroprotectant and low normal levels of peptide
hormone are associated with increased morbidity and mortality in
ischemic heart disease and stroke [13–15]. Exogenous IGF-1
reduces ischemic injury in many species [16–19], stimulates stroke-
induced neurogenesis [20] and promotes neuronal survival,
neuronal myelination and angiogenesis [21–22].
Age-related decline in IGF-1 is seen in virtually every species
[23] and in middle-aged female rats, loss of IGF-1 is paralleled by
declining levels of ovarian hormones such as estrogen. Estrogen is
also neuroprotective for stroke [24–26] and IGF-1 and estrogen
interact to promote neuroprotection in stroke models [27,28]. The
dual loss of these hormones may underlie the more severe
infarction seen in middle aged females as compared to young
females [29–30]. Our studies show that IGF-1 is neuroprotective
to middle aged females even when administered 4 h post stroke,
making this an attractive candidate for stroke therapy. IGF-1
therapy is also tolerated well in human patients [31], however its
capacity to promote tumor (including glioblastoma) growth and
metastasis [32,33], necessitates closely monitoring of its usage
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antagomirs to two miRNAs, miR1 and Let7f, with consensus
binding sites in the 39 UTRs of multiple IGF signaling pathway
components confer neuroprotection, while antagomir to a brain-
specific miRNA not associated with IGF signaling, was not
neuroprotective.
Results
Selection of therapeutic miRNA mimetics of IGF
We first identified by literature search and in silico analysis, two
microRNAs, miR1 and the Let7 family as candidate regulators of
IGF-1 signaling. Shown in Figure 1A are in silico predictions
(Targetscan.org; [34]) for vertebrate-conserved target sites for
miR1 and Let7f binding in the 39 UTR of the rat IGF1 gene.
Analysis of the published peer-review literature [35–42] as well as
in silico bioinformatics analysis (using several prediction algorithms,
Targetscan; www.targetscan.org, miRWalk; http://www.ma.uni-
heidelberg.de/apps/zmf/mirwalk, miRDB; http://mirdb.org/
miRDB/, and miRanda; http://www.microrna.org) indicates that
miR1 and the Let7 family are both functional antagonists of IGFs,
and Let7 potentially targets multiple components of the IGF
signaling pathway including IGF1 and 2, IGF1R, the IGF mRNA
binding and translation regulatory proteins, IGF2BP1, 2 and 3
and the IRS2, a signaling intermediary that couples IGF receptors
to intracellular signaling pathways. These analyses indicate that
suppressing miR1 and Let7 is both predicted and demonstrated to
promote IGF function in a variety of biological systems. In
contrast, both published literature and bioinformatics analysis did
not implicate miR124, a brain-specific miRNA, in IGF signaling.
PCR analysis of adult and middle-aged cortical tissue indicated
that expression of both miR1 and Let7f was elevated in middle-
aged females (10–12 m old) where IGF-1 levels are reduced, as
compared to adult females (5–7 m old) where IGF-1 levels are
higher (Fig. 1B). MiR124 expression was not altered with age. In
the following experiments, we therefore compared the effects of
suppressing miR1 and Let7f (as a prototype member of the Let7
family, conserved throughout vertebrate evolution, [43]), with the
effects of suppressing miR124 on functional recovery from stroke.
Effect of miRNA knock-down on infarct volume in female
rats
Adult female rats were subject to ischemia/reperfusion using
endothelin (ET)-1 induced Middle Cerebral Artery occlusion
(MCAo). ET-1 delivered to the middle cerebral artery causes a
cerebral cortical and striatal infarct typical of other MCAo models
[44,29,30]. Four hours after ET-1 injection, animals received an
intracerebroventricular (ICV) injection of either scrambled
Figure 1. Age-related changes in the expression of selected miRNA associated with the IGF-1 gene. A. Schematic depiction of the 39UTR
of the IGF-1 gene: miR1 and Let7 have preferentially conserved, 7–8 mer and 8 mer binding sites respectively on the 39UTR region of IGF-1 gene.
Nucleotides (nn) indicate the seed region for each microRNA. B. QPCR analyses of microRNA in the cerebral cortex of adult and middle aged females.
Expression of miR1 and Let7f is elevated in middle-aged (10–12 month) females as compared to adults females (5–7 month), while age does not
affect the expression of miR124, a brain-specific miRNA not associated with IGF-1. *: p,0.05.
doi:10.1371/journal.pone.0032662.g001
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cleotides (LNA-modified, Exiqon, Vedbaek, Denmark). Triphenyl
tetrazolium chloride (TTC)-stained brain slices from animals in
each group were analyzed for infarct volume. As shown in
Figure 2A, cortical infarct volume was significantly reduced (48%,
F(1,12): 7.182; p,0.05) by ICV injections of anti-miR1, as
compared to animals that received the control (scrambled
oligonucleotides). Striatal infarct volume was not significantly
altered by miR1 antagomir treatment. In contrast, Let7f
antagomirs profoundly reduced both cortical and striatal infarct
volume by 69.5% (F(1,8): 57.927; p,0.05) and 77.4% (F(1,8): 26.58;
p,0.05) respectively, as compared to the control group (Fig. 2B).
As an additional control, we also tested miR124, which has no
predicted binding site on the 39 UTR of the IGF-1 gene or in
other IGF signaling components, but is known to promote
neuronal differentiation [45]. Antagomirs to miR124 did not
affect either cortical or striatal infarct volume (Fig. 2C). In view of
the robust, region-independent effect of Let7f antagomirs,
subsequent studies focused specifically on this miRNA.
Sex difference in Let7f effects
We next determined whether Let7f was also neuroprotective in
males. As shown in Figure 3A, cortical or striatal infarct volume
was no different between male rats administered control
(scrambled) oligonucleotides and anti-Let7f treatment. To deter-
mine if the hormonal status of females contributed to the
neuroprotective effects of anti-Let7f, females were ovariectomized
3 weeks prior to ET-induced MCAo, to deplete endogenous levels
of ovarian hormones. As shown in Figure 3B, ovariectomy resulted
in loss of the protective effect of Let7f. The resulting infarct
volume was no different in ovariectomized females administered
anti-Let7f 4 h post stroke as compared to animals that received
scrambled oligonuleotides.
Behavioral assays
Anti-Let7f treatment to intact females also improved sensory
motor performance. As reported previously, MCAo impairs
performance on the vibrissae evoked forelimb placement test
[29,30]. On the ‘‘same-side’’ placement task, where the animal is
expected to reach out with the paw located on the same side as the
stimulated vibrissae, both control and anti-Let7f treated animals
were impaired post stroke (correct responses between 0–10%).
This is typical of all cortical-striatal infarcts and is relatively
insensitive to the severity or extent of tissue damage. On the ‘‘cross
midline’’ placement task, where the animal is expected to reach
out with the paw contralateral to the stimulated vibrissae, there
was a severe loss of right and left forelimb placement in the control
group post-stroke as compared to pre-stroke trials. However, in
animals treated with anti-Let7f there was no significant difference
between their pre- and post-stroke performance (p.0.05, Fig. 4A),
indicating that inter-hemispheric integration of forelimb place-
ment ability was maintained in anti-Let7f treated animals.
Figure 2. Effect of anti-sense miRNA on infarct volume. Female rats were injected with either anti-sense miRNA or scrambled oligonucleotides
(control) 4 h after ET-1 induced middle cerebral artery occlusion (MCAo). Infarct volume was assessed using TTC-stained brain sections and
quantitative morphometry. A. Animals injected with anti-miR1 had significantly lower cortical infarct volume as compared to controls injected witha
scrambled oligo. Striatal infarct was not significantly different between the two groups. B. Animals injected with anti-Let7f had significantly reduced
cortical and striatal infarct volumes as compared to controls. C. Animals injected with anti-miR124 had infarct volumes that were similar to the control
group. Histograms depict mean 6 SEM. *: p,0.05, n=5 per group.
doi:10.1371/journal.pone.0032662.g002
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Let7f treated animals as measured by time spent on the rotarod.
Post-stroke, anti-Let7f treated animals spent almost 2 fold more
time on the rotating rod as compared to the control group
(p,0.05, Fig. 4B).
Let7f regulation of target gene expression
To determine whether ICV injections of anti-Let7f treatment
resulted in local upregulation of Let7f target genes, we used
miRWalk, a comprehensive database that provides predicted and
validated microRNA targets, to identify a cluster of Let7f target
Figure 3. Sex difference in anti-Let7f treatment on infarct volume. A. Male rats received ICV injections of anti-Let7f 4 h post MCAo. Infarct
volumes assessed using TTC stained brain sections indicated that anti-Let7f treatment had no effect on the severity of cortical or striatal infarction. B.
Ovariectomized female rats received ICV injections of anti-Let7f 4 h post MCAo. Infarct volumes assessed using TTC-stained brain sections indicated
that anti-Let7f treatment had no effect on cortical or striatal infarction. Histograms depict mean 6 SEM, n=4–6 per group.
doi:10.1371/journal.pone.0032662.g003
Figure 4. Behavioral assessment of post-stroke anti-Let7f treatment. Animals injected with anti-Let7f or scrambled oligonucleotides 4 h
post MCAo were assessed on the vibrissae evoked forelimb placement task and the rotarod task. A. Control animals were impaired post stroke (blue
bars) on the cross midline task when the left vibrissa was stimulated (and required right paw placement), as compared to their pre-stroke (green bars)
performance. Anti-Let7f treated animals performed no differently from their pre-stroke performance indicating significant functional
neuroprotection. Histogram depicts percent correct responses+SEM, N=4–5/group, *: p,0.05. B. Animals were placed on a slowly-accelerating
rod and the amount of time spent on the rod was recorded. Post-stroke, anti-Let7f treated animals were able to maintain their balance on the
rotating rod for significantly longer than control treated animals. Histogram depicts time in seconds+SEM, N=5/group, *: p,0.05.
doi:10.1371/journal.pone.0032662.g004
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or function were selected for analysis. Of the 18 genes tested, 10
genes were significantly upregulated (p,0.05) in the ischemic
cortex of anti-Let7f treated animals (Fig. 5A). These include the
growth factor BDNF, the water channel protein Aquaporin-4,
enzymes related to sterol (DHCR24) and prostaglandin E2
synthesis (PTGES), genes related to synapse formation (syt4 and
MECP2), axonal transport (DCLK1) and cell survival (HYOU1).
Gene expression was also elevated in the striatum of anti-Let7f
treated animals in comparison to the scrambled controls (Fig. 5B),
some of these were similar to the ones seen in the cortex (BDNF,
PTGES, SYT4, SLC17A7) as well as genes coding for transcrip-
tional repressor (EZH2), transcription factor (NeuroD1) and
integrin B1 (ITGB1). None of these genes were upregulated in
the non-ischemic cortex (Fig. 5C). Furthermore, none of these
genes were upregulated in male animals subject to stroke followed
by anti-Let7f treatment (Fig. 5D).
Let 7f localization
In situ hybridization for Let7f combined with immunohistochem-
istry indicated that Let7f was colocalized occasionally with GFAP-
positive cells (astrocytes, Figure 6A, i), but most prominently with
CD11b-positive cells (Figure 6A, ii). Since CD11b is not an exclusive
marker for microglia, sections were further analyzed for Iba1, a
marker for activated microglia. Cells that were strongly labeled for
Iba1 had a ramified profile and did not express Let7f, however cells
that expressed low to moderate levels of Iba1 co-localized Let7f
(Figure 6A, iii). To ensure that Let7f expression in microglia was not
due to microglial phagocytosis, we further assessed miRNA
expression in these cells ex vivo. Microglia were harvested from the
ischemic and non-ischemic hemispheres and maintained in culture
for 2–4 days. Cultured cells were probed for Let7f and CD11b using
double in situ hybridization and immunohistochemistry. As seen in
Figure 6B, i, Let7f miRNA in situ labeling was seen in all CD11b-
positive cells. Additionally, microglial cultures exposed to FAM-
Figure 5. Anti-Let7f affects gene expression in the ischemic brain. RNA from the ischemic cortex and striatum was subject to quantitative
PCR for a subset of genes with validated 39 UTR binding sites for Let7f. Histograms represent gene expression normalized to cyclophilin (control)
expression in the cortex (A) and striatum (B). Approximately 10 genes were upregulated in animals that received anti-Let7f as compared to the
scrambled controls, indicating that the antagomir inhibited the actions of the endogenous miRNA. An asterisk (located by the gene name) indicates
genes that were significantly upregulated by anti-Let7f. A large subset (7/10) of these genes were upregulated by anti-Let7f in both the cortex and
striatum, while the remainder (3/10 in each case) were specific to either the striatum or cortex. (C) QPCR analysis of mRNA from the non-ischemic
cortex of anti-Let7 and control treated ischemic animals showed no changes in any of the target genes. (D) The same set of genes was also assessed
in males treated with anti-Let7f. None of these genes were significantly altered as compared to animals that received scrambled oligonucleotides,
consistent with the data that anti-Let7f was not neuroprotective in males. Primers and protein names can be found in Table S2. *: p,0.05.
doi:10.1371/journal.pone.0032662.g005
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nucleotide (Figure 6B, ii), indicating that this cell type is likely the
target of the anti-Let7f treatments in vivo.
Anti-Let7f increases microglial IGF-1 expression
Ischemic and non-ischemic cortical tissue from scrambled and
anti-Let7f infused animals was analyzed for IGF-1. As shown in
Figure 7A, IGF-1 expression was elevated in the ischemic cortex as
compared to the non-ischemic cortex, however, anti-Let7f treated
animals had IGF-1 levels similar to those that received scrambled
oligonucleotides. We next examined IGF-1 levels in microglia
exposed to anti-Let7f or scrambled oligonucleotides. Microglia
harvested from the ischemic cortex were exposed to antiLet7f or
scrambled oligonucleotides (0.25 mM) for 48 h and the media
analyzed for IGF-1. As shown in Figure 7B, anti-Let7f significantly
increased IGF-1 levels by 48.5% (p,0.05) as compared to cells
exposed to scrambled oligonucleotides.
Discussion
The present study provides novel in vivo evidence for a
therapeutic role for antagonists to Let7f and miR1 following
cerebral ischemia. We [30], and other research groups [17,46]
previously showed that IGF-1 microinjections protected the brain
Figure 6. Cellular localization of Let7f in vivo and ex vivo. A. Sections (40 um) from the ischemic cortex were probed for Let7f by in situ
hybridization (red) and either GFAP (green, Ai) or CD11b (green, Aii) immunohistochemistry. While Let7f was occasionally colocalized to GFAP-
positive cells, virtually all CD11b-positive cells were also Let7f labeled. In a parallel analysis, Let7f (green) was also localized to cells expressing
moderate levels of Iba1 (red; red arrow), but not in cells expressing high levels of Iba1 (white arrow). Bar: 200 mm. B. Microglial cells were harvested
from the ischemic cortex and cultured ex vivo for 2–4 days. (Bi) Combined in situ hybridization and immunohistochemistry indicated that all CD11b-
positive cells were also positively labeled with Let7f probes. (Bii) Microglial cultures exposed to FAM-labeled anti-Let7f in media readily incorporated
the antagomir. Shown here are confocal images of microglia (DIC illumination) with FAM-labeled antagomirs (green) Bar: 30 mm.
doi:10.1371/journal.pone.0032662.g006
Figure 7. Anti-Let7f regulates IGF-1 in microglia. A. IGF-1 levels in vivo: Cortical lysates from the ischemic and non ischemic hemisphere of
scrambled and anti-Let7f treated animals were analyzed for IGF-1 by ELISA. Ischemia induced a 4-fold elevation of IGF-1 in both scrambled and anti-
Let7f treated animals. However, IGF-1 levels in the anti-Let7f treated group was no different from that of the scramble controls. Histogram depicts
mean 6 SEM of 4–5 animals per group. B. IGF-1 levels in microglia: Microglia were harvested from the ischemic cortex of adult rats and treated in
culture with anti-Let7f or scrambled oligonucleotides for 48 h. Anti-Let7f treatment significantly increased IGF-1 levels in microglial media. Ex vivo
experiments were performed 6 times using cells harvested from 1–2 animals for each run; histogram depicts mean 6 SEM of all experiments.
*: p,0.05.
doi:10.1371/journal.pone.0032662.g007
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here, we set out to identify miRNA mimetics of IGF neuropro-
tection. Our two presumptive IGF pathway interacting miRNAs,
Let-7 and miR1 as well as our control, miR124, represent three
members of a small family of five miRNAs that have been
conserved throughout bilaterian evolution (from invertebrates to
mammals) [47], and the functions of the Let7 family, in particular,
exhibit strong evolutionary conservation [43]. Accordingly, we
reasoned that such highly-conserved miRNAs co-evolved stable
networks of regulated gene targets, and that our data from rodent
models was likely to be easily extrapolated to human disease. Both
in silico analyses using a variety of prediction algorithms, as well a
large body of experimental literature [35–42] indicated that Let-7
and miR1 target multiple components of the IGF signaling
cascade, ranging from mRNA binding proteins that coordinate the
translation of IGFs to members of the IGF family, their receptors
and downstream signaling pathways. Furthermore, both Let7f and
miR1 were elevated in middle-aged animals, where IGF-1 levels
are low. We therefore hypothesized that the suppression of either
Let7 or miR1 would recruit the activation of an evolutionarily
conserved network of genes to mimic IGF neuroprotection.
Our data indicate that anti-Let7f (a prototypic vertebrate-
conserved member of the Let7 family [43] or anti-miR1,
administered four hours following a stroke episode, is indeed
neuroprotective to mature female rats. Interestingly, while anti-
miR1 reduced infarct volume in the cortex, anti-Let7f reduced
infarct volume in both cortex and striatum. This generalized
neuroprotection exhibited by anti-Let7f exceeds that exhibited by
IGF-1 in female rats [30]. Like miR1, IGF1’s neuroprotection is
limited to the cortex. Therefore, the neuroprotection in both
cortex and striatum afforded by anti-Let7f suggests the recruitment
of mechanisms beyond those engaged by IGF1. Moreover, anti-
Let7f was overall more effective in inducing neuroprotection
following stroke compared to anti-miR1 suggesting that the Let7
family is likely to constitute a stronger therapeutic target for
interventional strategies following stroke. Importantly, anti-Let7-
mediated tissue preservation was also accompanied by preserva-
tion of sensory motor function including performance on the
rotorod test and on the contra-lateral vibrissae-induced forelimb
placement test. This latter test measures interhemispheric
integration of sensory motor information and anti-Let7f mediated
preservation of performance on this test following stroke indicates
a preservation of integrative neuronal pathways like those
projecting through the corpus callosum.
The present study also uncovers a sex difference in stroke-
related therapy. Unlike females, anti-Let7f treatment to age-
matched male rats had no neuroprotective effect. Sex differences
in post-stroke outcome can be influenced by the immediate
presence of sex hormones or prenatal hormone exposure or sex
chromosomes [48]. Sex differences have been noted in ischemia-
induced cell death pathways as well as the effectiveness of
neuroprotective compounds. For example, caspase activation is
enhanced in ischemic females and caspase inhibition benefits
females but not males in neonatal hypoxia [49] and adult ischemia
[50]. In contrast, reducing nitric oxide and inhibiting the DNA
polymerase PARP1 is neuroprotective for males but deleterious for
females [51,52]. Sex differences in cell death pathways and
neuroprotection may be related to the hormonal environment,
although the sex chromosomes may also play an important role. In
the present study, ovariectomy abolished the protective effect of
anti-Let7f in females, suggesting that miRNA action is influenced
by the hormonal milieu. In fact, several validated target genes for
Let-7f are also regulated by estrogen. A partial list includes the
neurotrophin BDNF, the water channel Aquaporin-4 (AQP4), the
tumor suppressor gene PTEN, the vesicular glutamate transporter
SLC17A7 and the sterol reductase DHCR24 which also functions
as a H2O2 scavenger.
Although Let7f has a consensus binding site on the IGF-1
39UTR, ICV infusions of anti-Let7f did not elevate IGF-1 mRNA
or protein levels in ischemic tissue when measured 5 days post-
stroke. IGF-1 protein was elevated on the ischemic hemisphere
irrespective of miRNA treatment, consistent with our previous
data [30]. One possible explanation is that IGF-1 accumulation at
the ischemic site is due to influx of peripheral (plasma) IGF-1,
gaining access to the brain due to a stroke-weakened blood brain
barrier. Another possibility is that that IGF-1 is regulated by the
anti-miRNA treatment at a time point not captured by the current
analysis. A more likely explanation, however, is that anti-Let7f acts
on a discrete cell type to alter local, but not global, availability of
IGF-1. This idea is supported by evidence that anti-Let7f
treatment increased IGF-1 in microglia, harvested from the
ischemic cortex 2d post-stroke. Microglia are the main effectors of
the innate response in the ischemic brain, however their role in
post-stroke pathogenesis is widely debated. Microglia release
cytotoxic molecules and attenuation of microglial activation
promotes neuroprotection [53]. However, microglia also synthe-
size IGF-1 at the ischemic site [54] and also respond to this peptide
by activation of PI-3K and Akt pathways. Furthermore, exogenous
application of microglia reduces ischemic injury [55] while
selective ablation of proliferating microglia exacerbates ischemic
injury and concomitantly reduces IGF-1 levels in the ischemic
hemisphere [56]. Microglia play a role in adult neurogenesis [57–
60] and proliferating microglia serve as an endogenous pool for
neurotrophic molecules. Hence, anti-Let7f action on microglia
may promote an alternate activation of this phagocytic cell
resulting in neuroprotection rather than inflammation. Recent
studies have recently shown that even in their resting state
microglia interact with neurons and astrocytes [61–62] and make
direct connections with neuronal synapses [63]. Hence, through its
actions on microglia, anti-Let7f may influence other cell types to
activate a wide array of genes.
While miRNA act as translational repressors, recent studies
indicate that target mRNA are also regulated, suggesting that
miRNA may act to destabilize or degrade RNA transcripts [64].
Hence, we examined other Let7f targets to determine the efficacy
of anti- Let7f action, focusing specifically on those genes involved
in neuronal survival. Anti-Let7f treatment upregulated 55% of
these selected mRNAs in the cortex and striatum as compared to
controls. Not all the tested genes were elevated by Let7f
antagomirs, reflecting the likelihood that Let7 is one of several
gene transcription/translation regulators that cooperatively and
dynamically alter gene expression following stroke, or alternative-
ly, adverse signal to noise ratio due to the fact that these genes are
expressed by small subsets of cells. It does however indicate that
gene expression was not simply a reflection of the extent of
neuroprotection, in which case all genes would be expected to be
elevated. Moreover, none of these genes were upregulated by anti-
Let7f in males, consistent with the fact that the antagomir did not
improve infarct volume in this sex. The loss of ovarian hormones
also rendered anti-Let7f treatment ineffective, suggesting that the
sex difference in anti-Let7f treatment is at least partly modified by
sex steroids. In fact, the ovarian hormone estrogen has been shown
to increase Let7f expression but suppresses miR1 [65], raising the
possibility that in intact animals in this study, Let7f antagomir
treatment may counteract estrogen-induced Let7f expression and
complement estrogen suppression of miR1.
In conclusion, a rapidly growing body of literature on miRNA’s
role in cancer [66], neurodegenerative diseases [67–72] and
MicroRNA Therapy for Stroke
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32662mental illness [73] strongly supports a therapeutic role for miRNA.
Manipulating endogenous miRNA levels by viral vectors or
modified oligoneucleotides to mimic or inhibit miRNA are
effective in vivo and in-vitro [74]. The present studies indicate a
useful strategy for identification of neuroprotective miRNA using
known neuroprotectant proteins as a starting point. Both anti-
Let7f and anti-miR1 were neuroprotective when administered
post stroke, but to differing extents, indicating that other clusters of
target genes regulated by these miRNA may critically determine
outcomes. A gene cluster based approach, focusing on genes
associated with specific disease pathways, may also be a useful
strategy. Finally, our data demonstrate a gender-specific role for
miRNA, where anti-Let7f mediated neuroprotection was only seen
in ovary-intact females, underscoring the importance of the
endocrine environment for miRNA actions.
Methods
Animals
All animals were purchased from Harlan Laboratories (IN).
Females were purchased as proven breeders with 3 pregnancies
(6–7 months, 230–320 g, n=65), while males (n=9) were age-
matched to females. All animals were maintained in a constant 12-
h dark:12-h light cycle in AAALAC-accredited vivarium facilities.
Food and water were available ad libitum.
Ethics Statement
All animal procedures were in accordance with NIH and
institutional guidelines governing animal welfare. An animal use
protocol was approved by the Texas A&M IACUC (Animal
Welfare assurance # A-3893-01).
Stereotaxic surgery
The animals were subjected to stereotaxic surgery to occlude the
left middle cerebral artery (MCAo) as reported previously [29] for
complete details of this procedure). Briefly, MCA occlusion was
induced by microinjecting 3 ml of Endothelin-1 (American Peptide
Company INC, CA; 0.5 mli n1ml PBS). Four hours post-stroke,
animals were administered intracerebroventricular (ICV) injec-
tions (ICV; coordinates 21.0 mm anterior posterior, +1.4 mm
medial lateral, 23.5 mm relative to the dural surface [75] of either
scrambled miR (control), anti-Let 7f, anti-miR1 or an unrelated,
anti-miR124 antisense LNA-oligonucleotide sequences, (termed
‘‘antagomirs’’, Exiqon, Vedbaek, Denmark). In each case, 8 ml
(25 mM) of the control or antagomir was microinjected over an 8-
minute period. This dose was based on manufacturer recommen-
dation (Exiqon, Vedbaek, Denmark) and a modification of a dose
reported for intraparenchymal injections of antagomirs [76] to
compensate for dispersion in CSF due to intracerebroventricular
injections). Animals were randomly assigned to treatment groups.
During surgery, rats were maintained at 37uC throughout and
oxygen saturation and respiratory rate were constantly monitored
using the Mouse Oximeter (STARR life sciences corp. PA). There
were no group differences in oxygen saturation and respiration
rate (Table S1). At termination, the brain was rapidly removed
and processed for TTC (Triphenyl Tetrazolium Chloride) staining
to assess infarct volume and biochemical analysis. All animals were
sacrificed on day 5 post-MCAo.
In a separate experiment, intact (uninjured) animals (n=5) were
injected ICV with anti-Let7f oligonucleotides and observed for 5
days. These animals displayed no ill-effects from receiving the
antagomir, maintained their normal body weight (273+7.38 gms
pre-injection, 273.6+5.18 post injection), and showed no differ-
ences on the vibrissae evoked forelimb placement task (100%
correct responses pre and post injection).
Infarct volume
Brain slices (2 mm thick) between 22.00 mm and +4.00 mm
from Bregma were incubated in a 2% TTC solution at 37uC for
20 min and later photographed using a Nikon E950 digital camera
attached to a dissecting microscope. Infarct volume was deter-
mined from digitized images using the Quantity One software
package (Bio-Rad CA). Typically 3 such slices were used for
analysis. The area of the cortical and striatal infarct was measured
separately in all slices in the ischemic and non-ischemic
hemisphere. Details of the volume determination are described
in [29–30]. The volume of the infarct was normalized to the
volume of the contralateral (non-occluded) hemisphere. To ensure
reliable and consistent detection of the infarct zone, images were
digitally converted to black and white and magnified, and all traces
performed by the same investigator (AS). Application of the
volume algorithm and statistical analysis was performed by a
separate investigator, blinded to experimental conditions (FS).
Behavioral assays
Motor impairment following MCAo was assessed using the
vibrissae evoked forelimb placement task as well as the rotarod
test. The vibrissae-elicited forelimb placement test [77,29] was
used both before and after the MCAo surgery. Animals were
subject to same-side placing trials and cross-midline placing trials
elicited by stimulating the ipsi and contra-lesional vibrissae (for a
detailed description of the procedure refer to 29). Rotarod test:
Motor performance of each rat was tested on the Rotarod
apparatus (IITC Life Science, CA) the day before MCAo for 3
trials that were 5 minutes in length (training). The animals were
tested post-MCAo at 24 hrs. If the animal fell off the beam before
30 seconds, the animal was given a 5 minute rest period, then
placed back on the beam for an additional 2 trials [78]. The length
of time spent (in sec.) on the beam was recorded.
Total RNA extraction
Total RNAs from the ischemic cortex of scrambled and anti-
Let7f treated males and females was isolated using RneasyH kit
(QIAGEN, Valencia, CA) and quantified using Agilent 2100
bioanalyzer (Agilent Technologies, Inc. Santa Clara, CA).
QPCR Analysis of Let7f-sensitive genes
Selected validated target genes for miR-Let-7f were identified
from the miRWalk (www.ma.uni-heidelberg.de/apps/zmf/mir-
walk/) database. Specifically, genes implicated in neuronal survival
and function, were selected for QPCR analysis. SYBR green based
RT-PCR using MyiQ
TM single-color RT-PCR detection system
(Bio-Rad, Hercules, CA) and gene specific primers sets (Rel Time
Primers, PA) were used to quantify the following genes, Ezh2,
Dll1, Mecp2, Notch1, Pouf4f2, Pten, Bdnf, Aqp4, Syt4, Ptges,
Hyou1, Stx1a, Dclk1, Neurod1, Itgb1, Dhcr24, Slc17a7, Mgst1
and Mmp9. Cyclophilin was used as an internal control.
Sequences for all primers are reported in Table S2.
In-situ hybridization and immunoflorescence
Female rats were euthanized 7d post stroke and the brains were
removed following intracardial paraformaldehyde perfusion.
Coronal brain sections (35 mm thickness) were incubated in pre-
hybridization solution (100% Formamide, 5 M Nacl, 50X
Denhart, 1 M DTT, 10 mg/ml tRNA and 100% Triton) at
45uC for 2 h. The sections were incubated overnight at 45uCi n
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oligonucleotide probe, Exiqon (Vedbaek, Denmark). The sections
were washed with 56 SSC at room temperature for 5 min
followed by a incubation in formamide wash solution (50%
Formamide, 0.1% Tween-20, 16 SSC and DEPC) at 45uC for
30 min. Sections were washed in 0.26SSC at RT for 30 min and
then subject to three 5 min washes with PBS followed by
incubation with Rhodamine Avidin or Fluorescein Avidin
(1:500, Vector, Burlingame, CA), for 1 h at RT. Following three
PBS washes the sections were incubated in the blocking solution
(NGS, triton, RNasin and 4 drops/ml of block of avidin blocking
solution) at RT for 1 h and then incubated ON with either anti-
GFAP (Sigma, St. Louis, MO), anti-CD11b (1:100, Serotec,
Raleigh, NC) or anti-Iba1 (1:100; Abcam, San Francisco, CA).
Sections were then washed in PBS and incubated with a secondary
antibody -goat anti-mouse (1:500, Molecular probes, Carlsbad,
CA) or goat anti-mouse (1:2000; Grand Island, NY). Finally, the
sections were rinsed, counterstained with Hoechst (Polyscience,
PA) and coverslipped with ProLong (Invitrogen, CA).
Microglial cultures
Female rats were subject to MCAo and terminated 48 hrs later.
Microglia were harvested using one of two procedures: In the first
procedure [79], cortical tissue from the ischemic and non-ischemic
hemisphere was dissected out under aseptic conditions and rinsed
56in dPBS with pennicillin/streptomycin. Thereafter, the tissue
was mechanically dissociated in Optimem (99%)/N2 (1%)
containing media and chemically in trypsin/EDTA for 20 min
at RT under sterile conditions. The cell suspension was
centrifuged at 700 rpm for 5 min at 18uC and the resultant cell
pellet was resuspended in serum containing media plated on poly-
d-lysine coated chambered slides and incubated at 37uC. Cells
were re-fed day 4 and 7, day 10 the cells were shaken (600 rpm for
15 min) and the media was collected and centrifuged at 700 rpm,
5 min, 18uC and the cells were re-plated in chamber slides at a
density of 50,000/chamber. On day 13, the media was collected
and the cells were gently fixed in 2% paraformaldehyde (1 h, room
temperature) and later processed for Let7f in situ hybridization
and CD11b immunohistochemistry. In other experiments, cultures
were exposed to FAM-labeled anti-Let7f (0.5 mM) in media
overnight. The following day, media was harvested and centri-
fuged at 1000 rpm for 20 sec at 4uC and stored at 220uC while
the cells were gently fixed as before, and coverslipped with Prolong
(Invitrogen, CA).
To maintain the ischemic phenotype, the second procedure
employed a rapid cell harvest protocol using CD11b antibodies
conjugated with magnetic beads (Miltenyi Biotec, CA) according
to the manufacturers protocol. Briefly, cortical tissue was collected
as above and subject to mechanical and chemical dissociation. Cell
suspensions were then filtered and incubated with anti-myelin
antibodies to remove myelin fragments. The partially purified cell
suspension was later incubated with anti-CD11b antibodies
conjugated to magnetic beads and separated on magnetic
columns. The resulting cell suspension was placed in chamber
slides (50,000/well) and maintained in culture for 48 h. Oligonu-
cleotide treatments were begun thereafter and 2 days later media
was collected and cultures fixed for immunohistochemistry. Media
was assayed for IGF-1 using an ELISA kit (Mouse/Rat IGF-1
Quantikine ELISA; R & D Systems, MN) using our previously
established procedures (30). Microglial cultures were rinsed and
fixed in 2% paraformaldehyde and subject to hybridization with
LNA modified Let7f oligonucleotide probe (described above) and
immunolabeled for CD11b.
Statistical Analysis
For infarct analysis, group differences were determined by 2-
way ANOVA coded for treatment and brain region by
multivariate analysis. For most other studies, group differences
were determined by Students t-test; for pre- and post-surgery
behavioral tests and microglial culture experiments, group
differences were determined by paired t-tests. In all cases,
differences were considered statistically significant at p,0.05.
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